Author's response to reviews

Title: Inhaled corticosteroids for abnormal pulmonary function in children with a history of Chronic Lung Disease of Infancy: study protocol [ISRCTN55153521]

Authors:

Saad A Alotaibi (saalotai@hotmail.com)
Sheldon S Spier (sheldon.spier@calgaryhealthregion.ca)
David D Johnson (david.johnson@calgaryhealthregion.ca)
Mark M Montgomery (Mark.Montgomery@calgaryhealthregion.ca)
Reginald R Sauve (Reginald.Sauve@calgaryhealthregion.ca)

Version: 2 Date: 30 March 2005

Author's response to reviews: see over
The manuscript revised and the formatting changes were done as requested by the reviewers into the following:

- **Title** - was changed as suggested to: Inhaled corticosteroids for abnormal pulmonary function in children with a history of Chronic Lung Disease of Infancy: study protocol [ISRCTN55153521]
- **Title & Abstract** - are changed to be identical in the manuscript and in the submission system.
- **Title page** was changed to include the following: the manuscript title and the full names, e-mail addresses and affiliations for all authors. The corresponding author is Saad Alotaibi.
- **Affiliations** - Each affiliation was written in full and provided in the following format: department, institute, city, country.
- **Each author was linked to their corresponding affiliation with the use of superscript numbers.**
- **Abstract** - Abstracts was structured into Background, Methods/Design, and Discussion. And updated the Abstract details on the submission page.
- **Manuscript sections** - Manuscript sections was organized in the following order: Abstract; Background; Methods/Design; Discussion;
  - Abbreviations ( were included as advised by the reviewers);
  - Competing interests was changed to reflect the 3M pharmaceutical company funding of the study.
  - Authors' contributions were changed to reflect each author contribution
  - Acknowledgements changed to reflect 3 M contribution
  - References no change has been done
- **Competing interests** was amended to reflect the funding from 3M pharmaceutical Canada company. And added ‘The authors declare that they have no competing interests’.
- **Authors' contributions** - Authors' contributions section was added as asked between the Methods and Acknowledgements.
- **Acknowledgements** - In the light of the funding letter from 3M Pharmaceuticals this section was changed as requested by the reviewers.
- **The manuscript was checked over very carefully for appropriate use of English.**